

FORM PTO-1390  
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

SHP-PT050

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

Not Known

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO.  
PCT/GB98/01587INTERNATIONAL FILING DATE  
June 1, 1998PRIORITY DATE CLAIMED  
June 2, 1997

TITLE OF INVENTION

ORGANOMETALLIC COMPLEXES




APPLICANT(S) FOR DO/EO/US Victor Christou

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.  A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a.  is transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  has been transmitted by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a.  are transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  have been transmitted by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
8.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.  An unsigned oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10.  The annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)) which include claim amendments upon which examination is sought.

**Items 11. to 16. below concern document(s) or information included:**

11.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.  A **FIRST** preliminary amendment.
  A **SECOND** or **SUBSEQUENT** preliminary amendment.
14.  A substitute specification.
15.  A change of power of attorney and/or address letter.
16.  Other items or information:  
 International Search Report (included with International Publication);  
 International Preliminary Examination Report;  
 Communication Under Rule 37 C.F.R. 1.53(b);  
 A check in the amount of \$894; and  
 Certificate of Express Mailing Accompanying Patent Application.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/445050		INTERNATIONAL APPLICATION NO. PCT/GB98/01587	ATTORNEY'S DOCKET NUMBER SHP-PT050																																																																								
<p>17. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p><b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b></p> <p>Neither international preliminary examination fee (37 CFR 1.482), nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$970.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$840.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$760.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00</p>																																																																											
<b>ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 840</b>																																																																											
<p>Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>23 - 20 =</td> <td>3</td> <td>X \$18.00</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td>0</td> <td>X \$78.00</td> </tr> <tr> <td>MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>0</td> <td></td> <td>+ \$260.00</td> </tr> <tr> <td colspan="3"><b>TOTAL OF ABOVE CALCULATIONS</b></td> <td><b>\$ 54</b></td> </tr> <tr> <td colspan="3">Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).</td> <td><b>\$</b></td> </tr> <tr> <td colspan="3"><b>SUBTOTAL</b></td> <td><b>\$ 894</b></td> </tr> <tr> <td colspan="4"> <p>Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> </td> </tr> <tr> <td colspan="3"><b>TOTAL NATIONAL FEE</b></td> <td><b>\$ 894</b></td> </tr> <tr> <td colspan="4"> <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property</p> </td> </tr> <tr> <td colspan="3"><b>TOTAL FEES ENCLOSED</b></td> <td><b>\$ 894</b></td> </tr> <tr> <td colspan="3"></td> <td><b>Amount to be: refunded</b></td> </tr> <tr> <td colspan="3"></td> <td><b>charged</b></td> </tr> <tr> <td colspan="4"> <p>a. <input checked="" type="checkbox"/> A check in the amount of <b>\$ 894</b> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of <b>\$</b> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>22-0493</u>. A duplicate copy of this sheet is enclosed.</p> <p>Our order no. is 1364</p> <p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b></p> </td> </tr> <tr> <td colspan="4"> <p>SEND ALL CORRESPONDENCE TO:</p> <p>VOLPE and KOENIG, P.C. 400 One Penn Center 1617 John F. Kennedy Boulevard Philadelphia, PA 19103</p> </td> </tr> <tr> <td colspan="4"> <p>  <b>SIGNATURE:</b>  Marilou E. Watson, Esquire</p> </td> </tr> <tr> <td colspan="4"> <p>NAME _____  42,213</p> </td> </tr> <tr> <td colspan="4"> <p>REGISTRATION NUMBER</p> </td> </tr> </tbody></table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	23 - 20 =	3	X \$18.00	Independent claims	3 - 3 =	0	X \$78.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)	0		+ \$260.00	<b>TOTAL OF ABOVE CALCULATIONS</b>			<b>\$ 54</b>	Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			<b>\$</b>	<b>SUBTOTAL</b>			<b>\$ 894</b>	<p>Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>				<b>TOTAL NATIONAL FEE</b>			<b>\$ 894</b>	<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property</p>				<b>TOTAL FEES ENCLOSED</b>			<b>\$ 894</b>				<b>Amount to be: refunded</b>				<b>charged</b>	<p>a. <input checked="" type="checkbox"/> A check in the amount of <b>\$ 894</b> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of <b>\$</b> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>22-0493</u>. A duplicate copy of this sheet is enclosed.</p> <p>Our order no. is 1364</p> <p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b></p>				<p>SEND ALL CORRESPONDENCE TO:</p> <p>VOLPE and KOENIG, P.C. 400 One Penn Center 1617 John F. Kennedy Boulevard Philadelphia, PA 19103</p>				<p>  <b>SIGNATURE:</b>  Marilou E. Watson, Esquire</p>				<p>NAME _____  42,213</p>				<p>REGISTRATION NUMBER</p>			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																																								
Total claims	23 - 20 =	3	X \$18.00																																																																								
Independent claims	3 - 3 =	0	X \$78.00																																																																								
MULTIPLE DEPENDENT CLAIM(S) (if applicable)	0		+ \$260.00																																																																								
<b>TOTAL OF ABOVE CALCULATIONS</b>			<b>\$ 54</b>																																																																								
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			<b>\$</b>																																																																								
<b>SUBTOTAL</b>			<b>\$ 894</b>																																																																								
<p>Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>																																																																											
<b>TOTAL NATIONAL FEE</b>			<b>\$ 894</b>																																																																								
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property</p>																																																																											
<b>TOTAL FEES ENCLOSED</b>			<b>\$ 894</b>																																																																								
			<b>Amount to be: refunded</b>																																																																								
			<b>charged</b>																																																																								
<p>a. <input checked="" type="checkbox"/> A check in the amount of <b>\$ 894</b> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of <b>\$</b> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>22-0493</u>. A duplicate copy of this sheet is enclosed.</p> <p>Our order no. is 1364</p> <p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b></p>																																																																											
<p>SEND ALL CORRESPONDENCE TO:</p> <p>VOLPE and KOENIG, P.C. 400 One Penn Center 1617 John F. Kennedy Boulevard Philadelphia, PA 19103</p>																																																																											
<p>  <b>SIGNATURE:</b>  Marilou E. Watson, Esquire</p>																																																																											
<p>NAME _____  42,213</p>																																																																											
<p>REGISTRATION NUMBER</p>																																																																											

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN**Docket Number (Optional)  
SHP-PT050

Applicant, Patentee, or Identifier: Victor Christou

Application or Patent No.: U.S. National Phase of International Application No. PCT/GB98/01587

Filed or Issued: International Filing Date: 1 June 1998

Title: ORGANOMETALLIC COMPLEXES

I hereby state that I am

- the owner of the small business concern identified below.  
 an official of the small business concern empowered to act on behalf of the concern identified below.

NAME OF SMALL BUSINESS CONCERN Isis Innovation Limited

ADDRESS OF SMALL BUSINESS CONCERN 2 South Parks Road, Oxford OX1 3UB,  
United Kingdom

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern may be directed to: Small Business Administration, Size Standards Staff, 409 Third Street, SW, Washington, DC 20416.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- the specification filed herewith with title as listed above.  
 the application identified above.  
 the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

- Each person, concern, or organization having any rights in the invention is listed below:  
 no such person, concern, or organization exists.  
 each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING T COOK

TITLE OF PERSON IF OTHER THAN OWNER Managing Director, Isis Innovation Limited

ADDRESS OF PERSON SIGNING 2 South Parks Road, Oxford OX1 3UB, United Kingdom.

SIGNATURE

DATE

5-1-00

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) &amp; 1.27(b))--INDEPENDENT INVENTOR</b>	Docket Number (Optional) <b>SHP-PT050</b>
---	--

Applicant, Patentee, or Identifier: Victor ChristouApplication or Patent No.: U.S. National Phase of International Application No. PCT/GB98/01587Filed or Issued: International Filing Date: 1 June 1998Title: ORGANOMETALLIC COMPLEXES

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- the specification filed herewith with title as listed above.
- the application identified above.
- the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- No such person, concern, or organization exists.
- Each such person, concern, or organization is listed below.

**Isis Innovation Limited, 2 South Parks Road,  
Oxford OX1 3UB, United Kingdom**

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

**Victor Christou**

NAME OF INVENTOR

Signature of inventor

NAME OF INVENTOR

Signature of inventor

NAME OF INVENTOR

Signature of inventor

January 5, 2000

Date

Date

Date

09/445050  
42C Rec'd PCT/PTO 01 DEC 1999  
Express Mail Label No.: EL404234792US

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the **PATENT APPLICATION** of:

Victor Christou

**Application No.:** Not Yet Known

Our File: SHP-PT050

**Filed:** Not Yet Known

Date: December 1, 1999

For: ORGANOMETALLIC COMPLEXES

Group: Not Yet Known

Examiner: Not Yet Known

**PRELIMINARY AMENDMENT**

Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination and before the calculation of the filing fee, please amend the application as follows:

**IN THE CLAIMS**

Please amend claim 3, line 1 by deleting "or claim 2".

Please amend claim 4, line 1 by deleting "any one of claims 1 to 3" and substituting therefor --claim 1--.

**Applicant:** Victor Christou  
**Application No.:** Not Yet Known

Please amend claim 5, line 1 by deleting "any one of claims 1 to 4" and substituting therefor --claim 1--.

Please amend claim 7, line 1 by deleting "any one of claims 1 to 6" and substituting therefor --claim 1--.

Please amend claim 8, line 1 by deleting "any one of claims 1 to 7" and substituting therefor --claim 1--.

Please amend claim 9, line 1 by deleting "any one of claims 1 to 8" and substituting therefor --claim 1--.

Please amend claim 10, line 1 by deleting "any one of claims 1 to 9" and substituting therefor --claim 1--.

Please amend claim 13, line 1 by deleting "or claim 12".

**Applicant:** Victor Christou  
**Application No.:** Not Yet Known

Please amend claim 14, line 1 by deleting "any one of claims 11 to 13" and substituting therefor --claim 11--.

Please amend claim 15, line 1 by deleting "any one of claims 11 to 14" and substituting therefor --claim 11--.

Please amend claim 17, line 1 by deleting "any one of claims 11 to 16" and substituting therefor --claim 11--.

Please amend claim 18, line 1 by deleting "any one of claims 11 to 17" and substituting therefor --claim 11--.

Please amend claim 20, line 1 by deleting "or claim 19".

Please amend claim 23, line 1 by deleting "either claim 21 or claim 22" and substituting therefor --claim 21--.

**Applicant:** Victor Christou  
**Application No.:** Not Yet Known

Please amend claim 23, line 2 by deleting "any one of claims 12 to 17" and substituting therefor --claim 12--.

**REMARKS**


The claims submitted for examination appear on original pages 26-28 and 30 and substitution pages 29 and 31 which are annexes to the International Preliminary Examination Report. This Preliminary Amendment amends those claims to delete reference to multiple dependent claims.

Early consideration and allowance of claims 1-23 are respectfully requested.

Respectfully submitted,

Victor Christou

By

  
Marilou E. Watson, Esquire  
Registration No. 42,213  
(215) 568-6400

VOLPE and KOENIG, P.C.  
400 One Penn Center  
1617 John F. Kennedy Boulevard  
Philadelphia, PA 19103

MEW/tc

3/2RPS

1

ORGANOMETALLIC COMPLEXES

This invention relates to organometallic complexes, processes for their production, light emitting materials incorporating the complexes and light emitting devices comprising the complexes or the materials. The devices of the invention may be flat panel displays.

Flat panel displays are the critical enabling technology for many current applications, including laptop computers and "heads up" displays, as they offer several potential advantages over conventional cathode ray tube displays, including compactness and low power consumption.

Currently, the flat panel display market is dominated by liquid crystal technology, but these materials suffer several drawbacks including small operational viewing angles, poor image contrast and high power consumption. As an alternative technology for flat panel displays, electroluminescent displays using semiconducting organic polymers offer the potential of lower cost, improved viewing angles, better contrast and lower power consumption. However, these materials often have broad emission profiles, resulting in poor chromaticity and reduced device efficiency.

Typically, a flat panel device is a multilayer assembly of structurally important films consisting of a transparent electrode, insulation, phosphor and metal electrode. All are important materials in device fabrication, but the single most important element in the

development of a multi-colour electroluminescent device is the phosphor.

It is known that organometallic complexes can be used as phosphors in electroluminescent devices. For example, US 5552547 describes complexes of aluminium, gallium and indium in which one of the ligands acts as a "built-in" fluorescent dye. The colour of the light which is emitted from the complex is determined by the ligand which acts as the dye.

It has been suggested that lanthanide complexes can be used as phosphors in electroluminescent devices.

M. A. Pavier et al., *Thin Solid Films*, 284-285 (1996) 644-647, describe electroluminescence from dysprosium- and neodymium- containing Langmuir-Blodgett films. The ligand used in the complexes is a pyrazolone-based molecule in which the binding to the metal by the ligand occurs via a beta-diketonate-type arrangement.

The europium complex with phenanthroline and thenoyltrifluoroacetone is disclosed in Sano et al, Jpn. J. Appl. Phys., vol.34 (1995), p. 1883-1887 and Campos et al in J. Appl. Phys., vol.80, no.12 (1996), p. 7144-7150. Both Sano et al and Campos et al teach the use of the complexes to provide red light in electroluminescent devices. Like the complexes disclosed by Pavier et al, it is the beta-diketonate part of the ligand which binds to the metal.

Campos et al mentions that fluorination of part of the beta-diketonate ligand imparts higher sensitising efficiencies to the complex. The sensitising efficiency of a complex is a measure of the efficiency of the process of energy transfer from the ligand to the metal during the excitation step associated with electroluminescence.

Fluorination of beta-diketonate ligands in organolanthanide complexes has been proposed as a way of shielding the metal ion from quenching by water molecules when the complexes are in aqueous solution; see Meshkova et al, Sov. J. Coord. Chem., 18, 183 (1992). However, in most light emitting devices, metal complexes are either in the form of a thin film or are dispersed in a polymer matrix in the substantial absence of water molecules and so quenching of the metal ion does not occur by this mechanism. Therefore, the teaching of Meshkova et al, which is based on ensuring that water molecules cannot get close to the metal, is of little relevance to organometallic complexes for use in light emitting devices.

The present invention aims to provide organometallic complexes in which the metal is a lanthanide (i.e., organolanthanide complexes) which are more effective phosphors for use in light emitting devices than the known complexes.

The invention also seeks to provide a ligand system for organolanthanide complexes which is effective with a range of different lanthanides in order that the same ligand can provide radiation from different parts of the electromagnetic spectrum, e.g.,


red, green or blue light and UV or IR radiation, simply by varying the metal in the complex.

It is a further aim of the invention to improve the radiative efficiency of organolanthanide complexes. The radiative efficiency of an organometallic complex is a measure of the amount of energy which is radiated from the complex relative to the amount of energy lost via non-radiative pathways. The known organolanthanide complexes have the problem that a number of non-radiative pathways are available for energy loss from the metal and their radiative efficiencies can therefore be relatively low.

The present invention, in one embodiment, is based on the finding that pyrazolyl species are highly effective ligands for producing organolanthanide complexes useful as phosphors in light emitting devices. Accordingly, the invention provides a light emitting device comprising a complex containing a lanthanide metal cation complexed with from one to three polydentate ligands, wherein each ligand comprises one or more pyrazolyl groups, optionally substituted and optionally fused with a substituted or unsubstituted, heterocyclic or carbocyclic, aromatic or non-aromatic, ring system, one of the nitrogen atoms of the pyrazolyl groups forming a coordinate bond to the metal.

Preferably, the ligands are trispyrazolylborate anions, the pyrazolyl groups being optionally substituted and optionally fused with a substituted or unsubstituted, heterocyclic or carbocyclic, aromatic or non-aromatic, ring system, optionally substituted at the boron atom.

Suitable complexes for use in the invention are desirably those having the formula (I):



wherein Z is a carbon atom or R<sup>1</sup> - B fragment


p is 1, 2 or 3

q is 3-p


A is a counterion

R<sup>1</sup> is: (i) hydrogen, aryl or aralkyl each optionally substituted with from one to five halogen or C<sub>1</sub> to C<sub>6</sub> alkyl groups; or (ii) C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> alkenyl or C<sub>1</sub> to C<sub>6</sub> alkynyl each optionally substituted with one or more halogen atoms

each L is covalently bound to Z and is independently selected from a group of the formula (II) or (III)



(II)



(III)

in which R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from: (i) halogen, cyano, nitro, sulphonato, amino, C<sub>1</sub>

to C<sub>6</sub> alkylamino, C<sub>1</sub> to C<sub>6</sub> alkylamido, carboxyl, C<sub>1</sub> to C<sub>6</sub> alkyloxycarbonyl, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, C<sub>1</sub> to C<sub>6</sub> alkylcarbonyloxy, C<sub>1</sub> to C<sub>6</sub> alkylcarbonyl C<sub>1</sub> to C<sub>6</sub> haloalkoxy and hydrogen; (ii) aryl or aralkyl each optionally substituted on the aryl ring or, for aralkyl, on the alkylene chain with from one or more of the groups mentioned under (i) above; and (iii) C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> alkenyl or C<sub>1</sub> to C<sub>6</sub> alkynyl each optionally substituted with one or more of the groups mentioned under (i) and (ii) above

or either R<sup>2</sup> and R<sup>3</sup> or R<sup>3</sup> and R<sup>4</sup> are linked so as to form a fused, aromatic or non-aromatic, ring system with the pyrazolyl ring of L

and M is a trivalent lanthanide metal ion. p is suitably 1 or 2 and is preferably 2.

The light emitting device of the invention may be a flat panel display.

The complexes of formula (I) in which R<sup>4</sup> and/or R<sup>2</sup> is -(CX<sub>2</sub>)<sub>n</sub>X wherein n is 0 or a positive integer from 1 to 6 and X is halogen; or R<sup>4</sup> and/or R<sup>2</sup> is orthodihalogenated or orthodihalomethylated aryl, optionally further substituted on the aryl ring (e.g., with from one to three halogen atoms or C<sub>1</sub> to C<sub>6</sub> alkyl groups) or in which R<sup>2</sup> and R<sup>3</sup> or R<sup>3</sup> and R<sup>4</sup> are linked so as to form a fused, aromatic or non-

aromatic, ring system with the pyrazolyl ring of L are believed to be novel and are also provided by the invention.

The term "alkyl" as used herein is intended to cover branched and unbranched C<sub>1</sub> to C<sub>6</sub> groups and alicyclic compounds for the C<sub>3</sub> to C<sub>6</sub> groups. The terms "alkenyl" and "alkynyl" are defined similarly with the only difference being that the groups may contain one or more unsaturated C=C bonds or C≡C bonds.

The term "aryl" covers C<sub>6</sub> to C<sub>10</sub> aromatic groups such as phenyl and naphthyl as well as heterocycles such as pyridyl, furyl and thiophenyl. The term "aralkyl" means C<sub>1</sub> to C<sub>3</sub> alkyl substituted with aryl, such as benzyl.

The term "halogen" means fluorine, chlorine, bromine or iodine. Of these, fluorine is the preferred halogen for the complexes of the invention.

Preferably, M is terbium (Tb), cerium (Ce), europium (Eu), erbium (Er), gadolinium (Gd), thulium (Tm), samarium (Sm) or neodymium (Nd). However, M may be another lanthanide metal such as praesodymium (Pr), for example. It will be appreciated that the metal is in the M (III) oxidation state in the complexes of the invention. The complexes with cerium, europium, erbium and gadolinium are preferred because they provide emissions of blue light, red light, IR radiation and UV radiation, respectively, and thus range across the electromagnetic spectrum. In electroluminescent devices, the complex with terbium unexpectedly gives blue light rather than the green light which is normally expected for terbium

complexes. This is particularly advantageous since cerium complexes which are conventionally used to produce blue light have the problem of a relatively wide bandwidth for the emitted light. The terbium complex of the present invention emits blue light with a narrower bandwidth than the previously used cerium compounds and so provides an improved alternative source of blue light for light emitting devices.

The trispyrazolyl ligands used in the invention have been found to be particularly effective in terms of their sensitising efficiency i.e., in transferring energy to the metal in the excitation step of the light emitting (e.g., electroluminescence) process. They also impart high radiative efficiencies to the complexes by providing few non-radiative pathways for relaxation (i.e., energy loss from the metal in its excited state). The ligands have been reported. Dias et al, Inorg Chem, 1995, 34, 1975 and 1996, 35, 267 and Renn et al Helv Chim Acta (1995), 78, 993 describe the synthesis of the fluorinated trispyrazolyl borate ligands. Julia et al., Organic Preparations and Procedures International, 16, 299, 1984, discloses the preparation of the trispyrazolylmethane-derived ligands.

The complexes of the invention are generally called "organometallic" herein. However, it will be understood by those skilled in the art that this term is used synonymously with the term "coordination". Also, the term "complex" as used herein covers both neutral species and compounds containing a charged organolanthanide species as part of a complex salt.


The present invention is also based on the wider finding that non-radiative pathways for relaxation in organolanthanide complexes can be provided by carbon-hydrogen bonds in the ligand which are relatively close to the metal and the discovery that these pathways can be blocked by fluorinating the ligand to replace the carbon-hydrogen bonds by carbon-fluorine bonds or otherwise designing the ligand such that there are no carbon-hydrogen bonds within 5 Å, preferably 8 Å, more preferably 10 Å, of the metal centre (i.e., the centre of the metal atom). Therefore, in another embodiment, the invention provides light emitting material comprising an organometallic complex either as a film or dispersed within a matrix of a polymer, the organometallic complex being a complex wherein the ligands are optionally fluorinated and arranged about the metal such that there are no carbon-hydrogen bonds within 5 Å of the metal centre.

The light emitted from the light emitting devices of the invention may be produced by various mechanisms such as electroluminescence, photoluminescence or cathodoluminescence with electroluminescence being preferred.

The matrix is preferably of the type conventionally used in light emitting (e.g., electroluminescent) devices and based on polymer systems such as polyvinylcarbazole (PVK) or polymethylmethacrylate (PMMA) with a hole transporting material such as 2-(4-biphenylyl)-5-(5-tertbutylbenzene)-1,3,4-oxadiazole (BBO). The organolanthanide complexes used in the invention may themselves act as electron transporting materials, separately from or in addition to being a phosphor, in the light emitting devices.

The ligands  $ZL_3$  used in the complexes of the present invention in which  $R^4$  and/or  $R^2$  is  $-(CX_2)_nX$  or optionally substituted orthodihalogenated or orthodiperhalomethylated aryl are particularly advantageous for use in the electroluminescent material of the invention since they provide complexes with no carbon-hydrogen (C-H) bonds within 5 Å of the metal centre. However, it will be appreciated that other ligands can achieve the same effect and thus also block the non-radiative pathways for relaxation. It is notable that in all of the known complexes for use in matrices in light emitting devices mentioned above, carbon-hydrogen bonds are available for non-radiative relaxation.

In the complexes of the invention,  $R^4$  and/or  $R^2$  is conveniently trifluoromethyl.  $R^3$  may be hydrogen and  $R^2$  trifluoromethyl. Alternatively,  $ZL_3$  may be:



The increased conjugation of the fused bi- and poly- cyclic systems can be advantageous for electron transfer within the complex.


Where the complexes used in the invention are positively charged, they will be provided by compounds containing the complex and a counterion. The counterion preferably should not provide non-radiative pathways for relaxation of the metal. Therefore, it is preferred that the counterion should not contain bonds between hydrogen and other atoms, such as carbon-hydrogen bonds. Trifluoromethylsulphonate,  $\text{CF}_3\text{SO}_3^-$ , halide (fluoride, chloride, bromide or iodide), nitrate,  $\text{NO}_3^-$ , and perchlorate,  $\text{ClO}_4^-$ , are suitable counterions for this purpose.

In yet another embodiment, the present invention provides a process for producing the complex of the invention which comprises the steps of reacting  $M^{3+}$  ions (i.e., trivalent lanthanide ions) with  $ZL_3$  anions in solution and separating the complex from the reaction mixture. The process is carried out in a suitable solvent at about or above room temperature up to the boiling point of the solvent for a time sufficient to form an extractable amount of the complex, preferably with stirring.

Preferably, the complex is separated from the reaction mixture by solvent extraction. To avoid the presence of water molecules in the complex which might provide non-radiative relaxation pathways, the process is preferably carried out under anhydrous conditions. It is also advantageous to exclude oxygen from the reaction mixture by

carrying out the process under an inert gas atmosphere e.g., of nitrogen or argon.

The process may be carried out via the following reaction:



wherein M' is a monovalent metal such as an alkali metal e.g., sodium or potassium, or thallium or silver (as  $Tl^+$  and  $Ag^+$ , respectively)

p,M,Z and L are as defined above,

and q is 3-p and A is a counterion.

In a preferred version of the process, two equivalents of  $M'ZL_3$  are suspended or dissolved in a solvent and are treated with one equivalent of a trivalent lanthanide salt. The reaction mixture is stirred for a period of time between one and 100 hours either at room temperature or at the boiling point of the solvent under standard conditions. The solvent is removed (for example, by evaporation under reduced pressure) and the complex separated from by-products by extraction into a solvent with a different polarity from that of the reaction solvent. The product is purified by crystallisation from either the extraction solvent or a combination of solvents with different polarities.

The invention is illustrated, by way of non-limiting example only, by reference to the drawings in which:

Figure 1 shows a simplified cross-sectional view of an electroluminescent device according to the invention, such as an organic flat panel display;

Figure 2 is a current versus voltage plot for an electroluminescent device according to the invention;

Figures 3, 4 and 5 are photoluminescence plots for europium, terbium and cerium complexes of the invention; and

Figure 6 is a plot of electroluminescence intensity versus wavelength for an electroluminescent device of the invention containing a terbium complex of the invention.


The device 10 of Figure 1 includes a substrate 1 which generally has a substantially planar surface 1a and may be a glass plate, although other suitable materials can be used for this purpose. An electrically conductive layer 2 is deposited on the planar surface 1a so as to form a relatively uniform electrical contact. Layers 3, 4 and 5 may be a single layer (for example, of the electroluminescent material of the present invention) comprising a mixture of conductive materials and luminescent dopant (such as a complex of the invention). However, it is known that this results in reduced device efficiency and a more efficient working device consists of a first organic layer 3 of a hole transporting material, the host emissive material 4 (such as the electroluminescent material of the invention), a second organic layer 5 of electron transporting material (which may comprise an organolanthanide of the invention also useful as a

phosphor) and a second electrically conductive layer 6 to form a second electrical contact.

It will be appreciated that light generated within the host emissive material 4 can be emitted either through first organic layer 3, conductive layer 2 and substrate 1 or through second organic layer 5 and second conductive layer 6. In the device 10 depicted in Figure 1, substrate 1 is formed of glass and conductive layer 2 is formed of organic and inorganic conductors, such as conductive polyaniline (PANI) or indium-tin-oxide (ITO), which are substantially transparent to visible light so that the emitted light exits downwardly through substrate 1 as the device 10 is shown in the Figure.

Device 10 has a potential applied between layers 2 and 6 by means of a potential source 7. In the embodiment of the invention shown in the Figure, conductive layer 2 is a p-type contact and conductive layer 6 is an n-type contact. The negative terminal of potential source 7 is connected to conductive layer 6 and the positive terminal is connected to conductive layer 2. Electrons injected through the n-type contact are transported through organic layer 5 and into organometallic layer 4 (the emissive layer). Holes injected from the p-type contact are transported through the organic layer 3 and into the organometallic layer 4 where, upon an electron and hole recombination, a photon is emitted.

The invention will now be further described by the following examples which are not intended to limit the scope of the invention in any way. In the examples, Tf = CF<sub>3</sub>SO<sub>3</sub><sup>-</sup> and

EXAMPLE 1

[Ce(Bpz)<sub>2</sub>(OTf)]

A mixture of Ce(OTf)<sub>3</sub> (1.0g, 1.65 mmol) and KBpz (1.1g, 3.31 mmol) in THF (100 mL) were stirred at room temperature, under N<sub>2</sub>. The solution gradually became yellow over 1 h. The mixture was left to stir for a further 14 h and the THF was then removed under reduced pressure to give a yellow residue. The product was extracted from the yellow residue with CH<sub>2</sub>Cl<sub>2</sub> (50 mL). Subsequent removal of the CH<sub>2</sub>Cl<sub>2</sub> *in vacuo* afforded the product as a pale yellow solid (0.69g, 47%). A photoluminescence plot for this complex is shown in Figure 5.

EXAMPLE 2[Tb(Bpz)<sub>2</sub>(OTf)]

A mixture of Tb(OTf)<sub>3</sub> (1g, 1.65 mmol) and KBpz (1.1g, 3.31 mmol) in THF (100 mL) was allowed to stir for 14 h. During this time a colourless precipitate formed. The THF was removed under reduced pressure, the colourless residue treated with CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 mL) and the supernatant filtered. Removal of the CH<sub>2</sub>Cl<sub>2</sub> under reduced pressure gave the product as a colourless microcrystalline solid (0.87g, 58%). A photoluminescence plot for this complex is shown in Figure 4.

An electroluminescent device was prepared using this complex as a phosphor. The device had a single layer structure consisting of a homogeneous mixture of the organometallic phosphor, an electron carrying material and a hole carrying material. This layer was deposited by spin-coating a stock solution of these materials onto an indium-tin oxide coated glass substrate in a dry nitrogen atmosphere. The stock solution was prepared in a dry nitrogen atmosphere using a mixture of the organometallic phosphor, polyvinylcarbazole (PVK) and 2-(4-biphenylyl)-5-(5-tertbutylbenzene)-1,3,4-oxadiazole (BBO). This solid mixture was then dissolved in THF to give a solution having the following concentrations: [Tb(Bpz)<sub>2</sub>(OTf)], 4.0 gdm<sup>-3</sup>; PVK, 20.0 gdm<sup>-3</sup>; BBO, 20.0 gdm<sup>-3</sup>. The counter electrode consisted of a magnesium contact overcoated with aluminium. A current versus voltage plot for the device is shown in Figure 2 and an electroluminescence intensity versus wavelength plot is shown in Figure 6.

EXAMPLE 3[Eu(Bpz)<sub>2</sub>(OTf)]

A mixture of Eu(OTf)<sub>3</sub> (1g, 1.67 mmol) and KBpz (1.11g, 3.30 mmol) was suspended in THF (100 mL) and the mixture stirred at room temperature for 12 h. A fine pale precipitate formed after 1 h and the solution became pale yellow in colour. The THF was removed *in vacuo* and the product was extracted from the resulting pale yellow solid with CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 mL). Evaporation of the CH<sub>2</sub>Cl<sub>2</sub> under reduced pressure gave the product as a pale yellow powder (1.16g, 78%). A photoluminescence plot for this complex is shown in Figure 3.

EXAMPLE 4[Er(Bpz)<sub>2</sub>(OTf)]

Er(OTf)<sub>3</sub> (2g, 3.25 mmol) and KBpz (2.19g, 6.51 mmol) were mixed together under N<sub>2</sub> and THF (100 mL) was added. A fine colourless precipitate formed during the first 1 h of the reaction, whilst the solution remained a pale pink colour. This mixture was left to stir for 12 h overnight and then the THF was removed under reduced pressure. The pale pink product was extracted from the residue with CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 mL) and isolated as a powder by evaporation of the solution under reduced pressure (2.46g, 83%).

EXAMPLE 5[Eu(Bpz)<sub>2</sub>(Cl)]

EuCl<sub>3</sub> (1g, 3.87 mmol) and KBpz (2.6g, 7.82 mmol) were mixed together under N<sub>2</sub> and THF (100 mL) was added. The resulting mixture was stirred for 1 h, by which time the solution had changed colour to orange and a fine colourless precipitate had formed. This mixture was left to stir for 14 h and then the THF was removed *in vacuo*. The product was extracted from the resulting pale yellow solid with CH<sub>2</sub>Cl<sub>2</sub> (2 x 50 mL) and the resulting solution was then evaporated to dryness giving a pale yellow powder. This powder was washed with hexane (50 mL) and recrystallised from hot toluene to give the product as a yellow solid (0.48g). A second crop of crystals (0.87g) was obtained by concentrating the toluene supernatant (1.35g, 45%).

EXAMPLE 6[Eu(Bpf)<sub>2</sub>Cl]

KBpf

A mixture of pf[H] (2.57 g, 12.6 mmol) and KBH<sub>4</sub> (0.12 g, 2.2 mmol) were suspended in dry decalin (20 mL) and the mixture was heated to 250 °C. After 4 h the mixture was cooled to room temperature and the pale yellow decalin solution filtered from the colourless sticky residue. The residue was triturated with pentane (50 mL), the pentane removed by filtration and the residue dried under reduced pressure to give the product as a colourless powder (0.62 g, 42 %).

$\text{Eu(OTf)}_3$  (0.257 g, 0.43 mmol) and  $\text{KBpf(DMAC)}$  (0.64 g, 0.86 mmol) were mixed under nitrogen and THF (100 mL) was added dropwise to the mixture at room temperature. After 26 hours, the THF was removed by vacuum and the product extracted from the resulting orange oil with THF (100 mL). The product was recovered from the THF solution as a pale brown solid by precipitation after concentration of the solution to 10 mL followed by addition of a large volume of hexanes (500 mL). The solid was dried under dynamic vacuum at room temperature for 4 hours.

Yield: 0.36 g (54%)

#### EXAMPLE 7

$\text{Tm(Bpz)}_2(\text{OTf})$

A mixture of  $\text{Tm(OTf)}_3$  (0.62 g, 1.0 mmol) and KBpz (0.67 g, 2.0 mmol) were dissolved in THF (50 mL) and the solution was stirred for 12 h at room temperature. A fine colourless precipitate developed within 1 h. After 12 h the THF was removed under vacuum and the product extracted from the resulting colourless solid with  $\text{CH}_2\text{Cl}_2$  (50 mL). Removal of the  $\text{CH}_2\text{Cl}_2$  *in vacuo* afforded the product as a colourless solid (0.72 g, 79 %).

#### EXAMPLE 8

$\text{Sm(Bpz)}_2(\text{OTf})$

A mixture of  $\text{Sm(OTf)}_3$  (1.97 g, 2.0 mmol) and KBpz (1.33 g, 4.0 mmol) were dissolved in THF (50 mL) and the solution was stirred for 48 h at room temperature. The THF was then removed under vacuum and the product extracted from the resulting

colourless solid with  $\text{CH}_2\text{Cl}_2$  (50 mL). Removal of the  $\text{CH}_2\text{Cl}_2$  *in vacuo* afforded the product as a colourless solid (1.59 g, 89 %).

EXAMPLE 9

$\text{Gd}(\text{Bpz})_2(\text{OTf})$

A mixture of  $\text{Gd}(\text{OTf})_3$  (1.21 g, 2.0 mmol) and KBpz (1.33 g, 4.0 mmol) in THF (50 mL) was stirred for 20 h at room temperature. The solvent was removed under reduced pressure and the product extracted from the solid residue with  $\text{CH}_2\text{Cl}_2$  (50 mL). Evaporation of the  $\text{CH}_2\text{Cl}_2$  under reduced pressure gave the product as a pale yellow solid (1.29 g, 62 %).


EXAMPLE 10

$\text{Nd}(\text{Bpz})_2(\text{OTf})$

A mixture of  $\text{Nd}(\text{OTf})_3$  (1.18 g, 2.0 mmol) and KBpz (1.33 g, 4.0 mmol) were dissolved in THF (50 mL) and the purple solution was stirred for 24 h at room temperature. A fine colourless precipitate developed within 1 h. After 24 h the solution was pink. The solvent was removed under vacuum and the product extracted from the resulting colourless solid with  $\text{CH}_2\text{Cl}_2$  (50 mL). Removal of the  $\text{CH}_2\text{Cl}_2$  *in vacuo* afforded the product as a purple solid (1.36 g, 77 %).

EXAMPLE 11

A mixture of Ce(OTf)<sub>3</sub> (0.59 g, 1.0 mmol) and KT<sub>Ind</sub> (0.81 g, 2.0 mmol) in THF (50 mL) was stirred at room temperature under N<sub>2</sub> for 20 h. The THF was removed under reduced pressure to give a yellow residue. The product was extracted from the yellow residue with CH<sub>2</sub>Cl<sub>2</sub> (50 mL). Removal of the CH<sub>2</sub>Cl<sub>2</sub> *in vacuo* afforded the product as a pale yellow solid (0.55 g, 54 %).

EXAMPLE 12


A mixture of Tb(OTf)<sub>3</sub> (0.61 g, 1.0 mmol) and KT<sub>Ind</sub> (0.81 g, 2.0 mmol) in THF (50 mL) was allowed to stir for 16 h, by which time a colourless precipitate had formed. The THF was removed under reduced pressure and the pale yellow residue was treated with CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and the yellow supernatant filtered from the colourless precipitate. Removal of the CH<sub>2</sub>Cl<sub>2</sub> under reduced pressure gave the product as a pale yellow solid (0.71 g, 69 %).

EXAMPLE 13

A mixture of Eu(OTf)<sub>3</sub> (0.60 g, 1.0 mmol) and KT<sub>Ind</sub> (0.81 g, 2.0 mmol) in THF (50 mL) was stirred for 20 h at room temperature. The solvent was removed under reduced pressure and the product extracted from the solid residue with CH<sub>2</sub>Cl<sub>2</sub> (50 mL). Evaporation


of the  $\text{CH}_2\text{Cl}_2$  under reduced pressure gave the product as a pale yellow solid (0.59 g, 57 %).

EXAMPLE 14




$\text{Tm}(\text{OTf})_3$  (0.62 g, 1.0 mmol) and  $\text{KT}_{\text{ind}}$  (0.81 g, 2.0 mmol) were dissolved in THF (50 mL) and the orange solution was stirred for 15 h at room temperature. The solvent was removed from the resulting cloudy solution and the yellow residue was washed with  $\text{CH}_2\text{Cl}_2$  (50 mL). The yellow filtrate was evaporated to dryness under reduced pressure, affording the product as a pale yellow solid (0.68 g, 65 %).

EXAMPLE 15



$\text{Sm}(\text{OTf})_3$  (0.60 g, 1.0 mmol) and  $\text{KT}_{\text{ind}}$  (0.81 g, 2.0 mmol) were dissolved in THF (50 mL) to give an orange cloudy solution. This mixture was stirred for 48 h and the solvent removed under reduced pressure. The product was isolated from the resulting yellow solid by extraction into  $\text{CH}_2\text{Cl}_2$  and then removal of the solvent under reduced pressure (0.731 g, 72 %).

EXAMPLE 16



$\text{Gd}(\text{OTf})_3$  (1.21 g, 2.0 mmol) and  $\text{KT}_{\text{ind}}$  (1.61 g, 4.0 mmol) were dissolved in THF (50 mL) to give a cloudy yellow solution. This


mixture was stirred for 16 h and then the solvent was removed. The product was extracted from the yellow residue with CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and isolated as a pale yellow powder upon removal of the CH<sub>2</sub>Cl<sub>2</sub> *in vacuo* (1.59 g, 77 %).

EXAMPLE 17




Nd(OTf)<sub>3</sub> (1.18 g, 2.0 mmol) and KT<sub>Ind</sub> (1.61 g, 4.0 mmol) were dissolved in THF (50 mL) and the lilac solution was stirred for 24 h at room temperature. The solvent was removed from the resulting cloudy solution and the lilac residue was washed with CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The lilac filtrate was evaporated to dryness under reduced pressure, affording the product as a lilac solid (1.27 g, 62 %).


EXAMPLE 18



Tb(OTf)<sub>3</sub> (1.21 g, 2.0 mmol) and KBpz<sup>12</sup> (2.23 g, 4.0 mmol) were suspended in THF (50 mL) and allowed to stir for 14 h. The initial colourless cloudy mixture cleared and became pale green during this time. The solvent was removed under reduced pressure and the colourless solid residue was extracted into CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The filtrate was concentrated to dryness to give the product as a colourless solid (2.00 g, 74 %).

EXAMPLE 19

$\text{Ce}(\text{OTf})_3$  (1.17 g, 2.0 mmol) and  $\text{KBpz}^{12}$  (2.23 g, 4.0 mmol) were suspended in THF (50 mL) and allowed to stir for 14 h. The initial colourless cloudy mixture cleared during this time. The solvent was removed under reduced pressure and the colourless solid residue was extracted into  $\text{CH}_2\text{Cl}_2$  (50 mL). The filtrate was concentrated to dryness to give the product as a pale yellow/green solid (1.59 g, 83 %).

EXAMPLE 20

$\text{Tb}(\text{OTf})_3$  (1.20 g, 2.0 mmol) and  $\text{KBpz}^{12}$  (2.23 g, 4.0 mmol) were suspended in THF (50 mL) and allowed to stir for 14 h. The initial colourless cloudy mixture cleared and became yellow during this time. Analysis of the product at this time showed only 1 ligand coordinated to the metal centre. The mixture was then heated at 85 °C for 6 h after which time the mixture was cooled to room temperature and the solvent was removed under reduced pressure to give a yellow solid residue, which was extracted into  $\text{CH}_2\text{Cl}_2$  (50 mL). The filtrate was concentrated to dryness to give the product as a pale yellow solid.

EXAMPLE 21

Tb(Bpz<sup>12</sup>)<sub>2</sub>(OTf)

Tb(OTf)<sub>3</sub> (1.20 g, 2.0 mmol) and KBpz<sup>12</sup> (2.23 g, 4.0 mmol) were suspended in THF (30 mL) and the mixture heated to reflux. After 6 h the mixture was cooled to room temperature and the solvent was removed under reduced pressure to give a yellow solid residue, which was extracted into CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and filtered from any insoluble residue. The filtrate was concentrated to dryness to give the product as a pale yellow solid.


EXAMPLE 22

Tb(Bpz<sup>14</sup>)<sub>2</sub>(OTf)

A mixture of Tb(OTf)<sub>3</sub> (0.61 g, 1.0 mmol) and KBpz<sup>12</sup> (1.11 g, 2.0 mmol) were suspended in THF (30 mL) and the mixture heated to reflux. After 7 h the mixture was cooled to room temperature and the solvent was removed under reduced pressure to give a yellow solid residue, which was extracted into CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and filtered from any insoluble residue. The filtrate was concentrated to dryness to give the product as a pale yellow solid (1.15 g, 86 %).

CLAIMS

1. Light emitting device comprising a complex containing a lanthanide metal cation complexed with from one to three polydentate ligands, wherein each ligand comprises one or more pyrazolyl groups, optionally substituted and optionally fused with a substituted or unsubstituted, heterocyclic or carbocyclic, aromatic or non-aromatic, ring system, one of the nitrogen atoms of the pyrazolyl groups forming a coordinate bond to the metal.
2. Device as claimed in claim 1, wherein the ligands are trispyrazolylborate anions, the pyrazolyl groups being optionally substituted and optionally fused with a substituted or unsubstituted, heterocyclic or carbocyclic, aromatic or non-aromatic, ring system, optionally substituted at the boron atom.
3. Device as claimed in claim 1 or claim 2, wherein the complex has the formula (I):



wherein Z is a carbon atom or R<sup>1</sup> - B fragment

p is 1, 2 or 3


q is 3-p and

A is a counterion


R<sup>1</sup> is: (i) hydrogen, aryl or aralkyl each optionally substituted with from one to five halogen or C<sub>1</sub> to C<sub>6</sub> alkyl groups; or (ii) C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> alkenyl or C<sub>1</sub> to C<sub>6</sub>

alkynyl each optionally substituted with one or more halogen atoms

each L is covalently bound to Z and is independently selected from a group of the formula (II) or (III)



(II)



or

(III)

in which R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently selected from: (i) halogen, cyano, nitro, sulphono, amino, C<sub>1</sub> to C<sub>6</sub> alkylamino, C<sub>1</sub> to C<sub>6</sub> alkylamido, carboxyl, C<sub>1</sub> to C<sub>6</sub> alkyloxycarbonyl, hydroxy, C<sub>1</sub> to C<sub>6</sub> alkoxy, C<sub>1</sub> to C<sub>6</sub> alkylcarbonyloxy, C<sub>1</sub> to C<sub>6</sub> alkylcarbonyl C<sub>1</sub> to C<sub>6</sub> haloalkoxy and hydrogen; (ii) aryl or aralkyl each optionally substituted on the aryl ring or, for aralkyl, on the alkylene chain with from one or more of the groups mentioned under (i) above; and (iii) C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> alkenyl or C<sub>1</sub> to C<sub>6</sub> alkynyl each optionally substituted with one or more of the groups mentioned under (i) and (ii) above

or either R<sup>2</sup> and R<sup>3</sup> or R<sup>3</sup> and R<sup>4</sup> are linked so as to form a fused aromatic or non-aromatic, ring system with the pyrazolyl ring of L

and M is a trivalent lanthanide metal ion.

4. Device as claimed in any one of claims 1 to 3, wherein M is Tb, Ce, Eu, Er, Gd, Tm, Sm or Nd.

5. Device as claimed in any one of claims 1 to 4, wherein R<sup>4</sup> and/or R<sup>2</sup> is -(CX<sub>2</sub>)<sub>n</sub>X, wherein n is 0 or a positive integer from 1 to 6 and X is halogen, or orthohalogenated or orthodiperhalomethylated aryl.

6. Device as claimed in claim 5, wherein R<sup>4</sup> and/or R<sup>2</sup> is trifluoromethyl.

7. Device as claimed in any one of claims 1 to 6, wherein R<sup>3</sup> is hydrogen and R<sup>4</sup> and/or R<sup>2</sup> is trifluoromethyl.

8. Device as claimed in any one of claims 1 to 7, wherein Z is H-B.


9. Device as claimed in any one of claims 1 to 8, wherein the complex is positively charged and is derived from a compound containing CF<sub>3</sub>SO<sub>3</sub><sup>-</sup>, halide, nitrate or perchlorate as the counterion.

10. Device as claimed in any one of claims 1 to 9 which is a flat panel display.

RE 24  
M 05-06-99

29

11. Organometallic complex having the formula (I)



wherein Z, p, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, L, A, q and M are as defined in claim 3 and:

R<sup>4</sup> and/or R<sup>2</sup> is -(CX<sub>2</sub>)<sub>n</sub>X wherein n is 0 or a positive integer from 1 to 6 and X is halogen; or R<sup>4</sup> is orthodihalogenated or orthodiperhalomethylated aryl, optionally further substituted on the aryl ring; or

R<sup>2</sup> and R<sup>3</sup> or R<sup>3</sup> and R<sup>4</sup> are linked so as to form a fused aromatic or non-aromatic ring system with the pyrazolyl ring of L.


12. Complex as claimed in claim 11, wherein M is Tb, Ce, Eu, Er, Gd, Tm, Sm or Nd.

13. Complex as claimed in claim 11 or claim 12, wherein R<sup>4</sup> is trifluoromethyl.

14. Complex as claimed in any one of claims 11 to 13, wherein R<sup>3</sup> is hydrogen and R<sup>2</sup> is trifluoromethyl.

15. Complex as claimed in any one of claims 11 to 14, wherein Z is H-B.

16. Complex as claimed in claim 11, wherein  $ZL_3$  is



17. Complex as claimed in any one of claims 11 to 16, wherein A is  $CF_3SO_3^-$ , halide, nitrate or perchlorate.

18. Process for producing the complex of any one of claims 11 to 17 comprising the steps of reacting  $M^{3+}$  ions with  $ZL_3^-$  ions in solution and separating the complex from the reaction mixture.

19. Process as claimed in claim 18, wherein the complex is separated from the reaction mixture by solvent extraction.

20. Process as claimed in claim 18 or claim 19 which is carried out under substantially anhydrous conditions.

21. Light emitting material comprising an organometallic complex either as a film or dispersed within a matrix, the organometallic complex being a complex according to claim 11, wherein the ligands are optionally fluorinated and are arranged about the metal such that there are no carbon-hydrogen bonds within  $5\text{\AA}$  of the metal centre.
22. Light emitting material as claimed in claim 21, wherein the ligands are tridentate and there are two ligands per metal ion in the complex.
23. Light emitting material as claimed in either claim 21 or claim 22, wherein the complex is a complex according to any one of claims 12 to 17.

1/3




FIG. 1




FIG. 2

2/3




FIG. 3




FIG. 4




FIG. 5




FIG. 6

Please type a plus sign (+) inside this box → **[+]**

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

Declaration  
Submitted  
with Initial  
Filing

OR

Declaration  
Submitted after Initial  
Filing (surcharge  
(37 CFR 1.16 (e))  
required)

Attorney Docket Number		SHP-PT050
First Named Inventor		Victor Christou
COMPLETE IF KNOWN		
Application Number	Not Yet Known	
Filing Date	Not Yet Known	
Group Art Unit	Not Yet Known	
Examiner Name	Not Yet Known	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**ORGANOMETALLIC COMPLEXES**

the specification of which

*(Title of the Invention)*

is attached hereto  
OR

was filed on (MM/DD/YYYY) **06/01/1998** as United States Application Number or PCT International

Application Number **PCT/GB98/01587** and was amended on (MM/DD/YYYY) **12/01/1999** (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	YES	NO
9711237.9	Great Britain	06/02/97	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ➔ 

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number <i>(if applicable)</i>

Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Customer Number  → *Place Customer Number Bar Code Label here*

Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Alfred Stapler	16,675	Glenn M. Massina	40,081
Anthony S. Volpe	28,377	Marilou E. Watson	42,213
C. Frederick Koenig III	29,662	Jeffrey M. Glabicki	42,584
Gerald B. Halt, Jr.	37,633	Kao Lu	43,761
Salvatore Anastasi	39,090		

Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to:  Customer Number or Bar Code Label  OR  Correspondence address below

Name  VOLPE and KOENIG, P.C.

Address

Address

City  State  ZIP

Country  Telephone  Fax

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:  A petition has been filed for this unsigned inventor

Given Name (first and middle if any)  Family Name or Surname

Inventor's Signature  Date

Residence: City  State  Country  United Kingdom  Citizenship

Post Office Address

Post Office Address  GBX

City  State  ZIP  OX1 3QR  Country  United Kingdom

Additional inventors are being named on the \_\_\_\_\_ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto